Illumina, Inc. (ILMN) Earnings Call Transcript & Summary

April 30, 2026

NASDAQ US Health Care Life Sciences Tools and Services earnings 56 min

Earnings Call Speaker Segments

Conor McNamara

executive
#1

Good day, everyone, and thanks for joining us for Illumina's first quarter 2026 earnings call. On today's agenda, we'll go over the financial results we issued following the market close, share some prepared comments, and then take your questions. You can find our earnings release in the Investor Relations portion of illumina.com. With me this afternoon are Jacob Thaysen, our Chief Executive Officer, and Ankur Dhingra, our Chief Financial Officer. Jacob will kick things off with a business update, and after that Ankur will walk through our financials. During this call, we'll reference certain non-GAAP financial measures, and you can find a reconciliation to GAAP in today's release as well as in the supplementary data posted on our website. Except where noted, every growth rate we cite is on a year-over-year reported basis. Organic growth excludes the effects of currency and acquisitions, while Rest of World organic growth further excludes the impact from our Greater China region. As a reminder, effective January 2026, we revised our geographical reporting segments so they line up better with the corresponding commercial organizational structure, and the supplementary file on our website lays out historical results under the new geographic reporting. This call is being recorded, and a replay will be posted on our website. We intend for all forward-looking statements made on today's call to be protected under the Private Securities Litigation Reform Act of 1995. For a better understanding of the risks and uncertainties that might cause actual results to differ, please refer to the documents Illumina files with the SEC, including our most recent Forms 10-Q and 10-K. With that, I'll hand the call over to Jacob.

Jacob Thaysen

executive
#2

Thanks, Conor, and good afternoon to all of you. We've gotten off to an excellent start in 2026, with Q1 revenue, margin, and EPS each landing above the range we had guided. That strong showing speaks to disciplined execution throughout the organization, plus momentum in our clinical markets and growth in every region except China. Keeping our attention on what we deliver for customers and shareholders is driving the durable success that sets us up for further growth far into the future. Because of the Q1 outperformance, we're lifting our 2026 guidance, and we'll get into the specifics of that later on in our prepared remarks. I'd like to call out and thank the whole Illumina team for the way they've navigated a higher cost environment while still maintaining strong operational performance and providing the quality and reliability our customers count on. When it comes to Q1, I'll concentrate on three things: our disciplined commercial execution with ongoing momentum in clinical end markets, product innovation and road map updates from our R&D team during the quarter. And the progress we're making against our long-term strategy and targets. All in all, I'm quite pleased with how the company performed in Q1, which gives us greater confidence that our strategy is working. Extending the momentum from 2025, our team turned in yet another quarter of solid performance. Among the quarter's highlights: Rest of World organic growth of 3.5%, above the high end of our guidance, powered by strength in sequencing consumables and instruments, roughly 7% growth in Rest of World sequencing consumables, including about 20% growth in clinical, which reflects continued adoption of sequencing-based diagnostics and more sequencing-intensive applications. More than 80 NovaSeq X placements during the quarter, about 20 more than Q1 '25, with placements growth year over year in both clinical and nonclinical markets. New high-volume clinical applications are being built on the NovaSeq X as the platform becomes more embedded in clinical workflows and supports continued consumables growth over time. The SomaLogic acquisition closed successfully, with the business performing in line with our expectations on both revenue and profitability. Margins roughly 150 basis points above guidance, driven by solid revenue performance and disciplined expense management in higher cost environment. Taken together, these results reflect our consistent execution and how we dedicated resources to best capitalize on a growing and evolving market. The investments Illumina has made over the last 2 decades to make sequencing technology more accessible are driving meaningful impact with continued clinical demand. Clinical accounted for more than 65% of our sequencing consumables revenue in the quarter, driven by both the expansion of sequencing-based diagnostics and the increased use of more data-intensive applications. Customers are launching new assays with ongoing progress in reimbursement, supporting broader adoption of sequencing in clinical decision-making. Meanwhile, appetite is rising for methods like comprehensive genomic profiling and whole genome sequencing. That trend pushes sequencing intensity upward, and here the NovaSeq X is taking on a more and more pivotal part as customers expand those applications. We foresee a lengthy path for ongoing expansion within our clinical business. Over in research and academic markets, demand stays guarded while customers work through funding uncertainty, yet our confidence in the long-term opportunity across these end markets holds firm, and we keep putting money into leading technologies, among them proteomics and single cell, with further offerings in spatial in progress. Such markets act as a key gateway for new technologies, which helps propel long-term clinical adoption down the road. Customer enthusiasm for our new product offerings stays strong. And once funding uncertainties begin to subside, we anticipate a return to growth across research and academic markets. During this quarter, our innovation strategy also became evident in the way we broaden the value of our platform for our customers. At AGBT, we zeroed in on how our end-to-end workflow approach is assisting customers in unlocking new discoveries and producing deeper insights, with the quality and reliability that only Illumina can offer. This approach of ours is turning into a significant shift in the way customers assess solutions, not merely at the instrument level but throughout the full workflow. We pointed to several illustrations of this at AGBT. We rolled out TruPath, which enables whole genome sequencing with deeper insight while doing away with traditional library prep, cutting hands-on time down to roughly 10 minutes. Customers are demonstrating considerable interest, especially in areas such as rare disease, where some are employing it to streamline the standard of care by merging multiple types of tests into one TruPath workflow; that helps them reach answers more quickly and with greater confidence relative to traditional approaches. A number of customers are already at different stages of clinical studies with TruPath, and we anticipate customer demand will keep climbing over the coming quarters. We likewise witnessed very high engagement surrounding our spatial transcriptomics offering, which stands as a solid illustration of how we innovate alongside our customers to meet their needs. Early access users have demonstrated that the offering can produce data in highly challenging sample types, for instance lymphatic tissue that was previously hard to study. We stay on track to launch later this year and look forward to delivering this capability to the market. Meanwhile, we keep broadening what customers are able to do on the NovaSeq X. We unveiled our 18-month road map, covering new 14B and 35B flow cells, staggered flow cells run and our capacity to enhance data quality with the Q70 performance. These innovations on the X will deliver more flexibility, boost throughput and sharpen overall workflow efficiency for our customers. Such introductions and platform improvements are fueling higher NovaSeq X placements and greater demand, even 3 years after we shipped our first X instrument. We wrapped up the quarter with a strong backlog, and that gives us the confidence to lift our outlook for instruments for the entire year. When we take a step back and examine the quarter, the biggest point is that our strategy is delivering. We keep adding value to the NovaSeq X by innovating continuously, and that shows up in our financials as customers scale up and broaden what they run on the platform. As sequencing pushes further into clinical and research environments, customers are running additional samples, producing additional data, and depending on applications that are more sequencing-intensive. That's exactly where the NovaSeq X keeps playing a central role. By expanding what customers are able to do on the platform, we allow them to accomplish more with the systems they already own and to handle more complex applications as time goes on. That gives them confidence they can use their X far into the future to fuel their own success. When our customers succeed, that success appears in our results. We're also bringing this into data and AI through BioInsight, which we launched late last year to help customers speed up discovery. One key program inside BioInsight is the Billion Cell Atlas, which we launched earlier this year to better understand how genes cause disease through Perturb-seq. We're seeing rising interest from partners, with more companies wanting to take part. With hundreds of millions of cells already produced, customers are beginning to see insights that can underpin AI-driven models for drug discovery. Now to our outlook. Building on this year's strong start, we're updating our outlook compared with the guidance we gave in Q4. Importantly, the current end market dynamics we're observing line up with what we anticipated heading into 2026. Clinical keeps leading, while research and applied stay more cautious. Our first quarter performance beat expectations, and we're raising our full year revenue outlook; the driver is the strength in our business and how it carries into the remainder of the year; we're also raising our operating margin expectations and EPS outlook, reflecting the Q1 outperformance and higher revenue; we also remain on track toward our 2027 targets, and the investments we're making in R&D and product innovation put us in position to deliver high single-digit revenue growth, continued margin expansion and double-digit to teens EPS growth for years ahead. I want to thank the whole Illumina team, our customers and all our stakeholders for another excellent quarter. I also want to thank our three outgoing Board members for their years of service and contribution to Illumina. I'm very proud of how Illumina has progressed since I joined the company in 2023, especially given the dynamic macro environment we've been operating in; with that, I'll hand it over to Ankur to walk through the financial details before we move to Q&A.

Ankur Dhingra

executive
#3

Thanks, Jacob, and hello everybody this afternoon. I'll go over the financial results for our first quarter, give you some added detail regarding revenue, expenses, earnings, along with our balance sheet and capital deployment, and after that talk about the outlook we've updated. Before diving into the specifics of how we performed financially, let me offer a big-picture sense of how Q1 unfolded. Illumina's revenue during the first quarter reached $1.09 billion, which landed $20 million higher than the midpoint of the guidance we gave, mostly because instrument sales did better than anticipated — we placed over 80 NovaSeq X instruments during the quarter, exceeding the 50 to 60 per quarter range we had targeted. Clinical consumable sales likewise finished at the upper end of what we expected for the quarter. That stronger revenue carried through into margins and EPS, with non-GAAP diluted EPS coming in roughly $0.10 above the midpoint of the guidance we provided. So now let's turn to specifics. In Q1, Illumina's revenue of $1.09 billion rose 4.8% versus a year earlier and 1.2% organically, with currency and acquired revenue each adding just under 2 percentage points to the growth rate we reported. Organic growth in Rest of World was 3.5%. Sequencing consumables revenue reached $726 million, climbing 4% compared with a year ago, with Rest of World organic growth at 5%, which was roughly consistent with what we expected. High throughput volume accounted for most of the revenue increase, since the NovaSeq X installed base keeps growing and utilization rose versus a year earlier. Demand for clinical sequencing consumables keeps expanding, up 20% excluding China for a second quarter in a row. Ongoing growth in clinical volumes among our customers, plus uptake of information-rich, sequencing-intensive tests in new trials, is fueling strong demand across clinical market applications; we see substantial growth opportunities in clinical markets as we help customers broaden their applications throughout the Illumina ecosystem. That covers easier access to expanded information sets for offerings such as 5-base and TruPath. Sequencing consumables in research and applied fell 12% excluding China, which mirrors the ongoing uncertainty around funding that persisted during the quarter. Although macro commentary regarding the funding picture seems stable to improving, trends so far this year have stayed in line with what we expect for 2026. As of Q1, roughly 82% of volumes and 55% of revenue have shifted onto NovaSeq X. 90% of research and applied volume now sits on the X, and we're well positioned to get back to revenue growth once that market returns to a more normalized level of activity. 76% of clinical volume now sits on the X, and we still expect that most clinical volumes — over 80% to 85% — will be on X by the close of 2026; on sequencing activity, total sequencing GD output across our connected high- and mid-throughput instruments again rose more than 30% compared with a year earlier, with clinical growth far exceeding that. Sequencing instruments revenue of $118 million increased 9% versus a year ago in Q1 and rose 10% on a Rest of World organic basis, fueled by higher sales of NovaSeq X. During the first quarter, we shipped more than 80 NovaSeq systems, and interest in that platform stayed robust, particularly across clinical, where we booked a number of multiunit orders during the period. In fact, throughout Q1, we couldn't supply enough NovaSeq X units to meet orders because demand kept coming in very strong. Placements of high-throughput instruments in research likewise rose compared with a year earlier. Sequencing service and other revenue reached $151 million, which represented a 7% increase versus a year ago and a 5% gain on a Rest of World organic basis. As BioInsight scales, the timing of strategic partnerships and data deals may prove uneven within this segment. The Microarrays business declined 20% on a Rest of World organic basis, driven mainly by certain large customers in the direct-to-consumer segment. Turning to the remainder of the P&L. Non-GAAP gross margin came to 68.2% in the first quarter, 80 basis points higher than a year ago, helped by cost efficiencies and greater revenue, partially offset by tariffs. Non-GAAP operating expenses totaled $506 million, a 3% year-over-year increase that mostly reflects bringing the SomaLogic team on board. Non-GAAP operating margin for Q1 was 21.9%, roughly 150 basis points wider than the prior year, which shows greater operating leverage from our better cost structure. Looking beneath the line, non-GAAP other expense, mostly net interest expense, came to $15 million, while the non-GAAP tax rate was 20.5%. Average diluted shares stood at roughly 154 million, $5 million fewer than a year earlier, as a result of share repurchases made across the year. Taken together, non-GAAP EPS was $1.15 per diluted share, an increase of about 19% versus a year ago and roughly $0.10 above the midpoint of the guidance range we gave in February. Shifting to cash flow, balance sheet and capital allocation matters for the quarter. Operations provided $289 million in cash during the quarter. Capital expenditures totaled $38 million, and free cash flow for Q1 was $251 million. During Q1, we bought back 2 million shares of Illumina stock for about $242 million, at an average price of $120.85 per share. At the close of the quarter, roughly $400 million remained available under our existing share repurchase authorization, and we plan to keep buying back shares when opportunities arise. We also announced today that Illumina's Board of Directors has approved an extra $1.5 billion for share repurchases. In the quarter, we completed the SomaLogic acquisition on January 30, for a net cash payment of $363 million, plus possible royalties and milestone payments. After the quarter ended, we paid the first milestone of $25 million tied to achieving certain 2025 targets; we finished the quarter with about $1.16 billion in cash, cash equivalents and short-term investments, and gross leverage of roughly 1.5x gross debt to last 12 months EBITDA. All in all, 2026 got off to a strong start, which lets us lift our full year guidance and strengthens our confidence in the progress we're making toward our long-range targets. Now on to guidance for year 2026, beginning with revenue. Our guidance for reported revenue is going up by $20 million, reflecting how we outperformed in Q1, and the range we now anticipate is $4.52 billion to $4.62 billion. Revenue from acquisitions should still add 1.5 to 2 points of growth, while currency is anticipated to contribute roughly 1% of growth. That puts our guidance near the top of the growth rate targets we laid out before, which include 2% to 4% organic growth for Rest of World. End market demand overall is tracking with what we anticipated as we came out of 2025: demand growth stays strong in clinical markets, while research and applied markets face funding uncertainty. Within Rest of World organic sequencing revenue growth, our expectation is unchanged for low to mid-single-digit growth in consumables, with clinical expanding at a double-digit to mid-teens rate and research and applied shrinking at a mid- to high single-digit rate. Our instrument guide is being lifted to flat to low single-digit growth year-over-year, powered by very strong NovaSeq X demand. As I noted, supply constraints held us back in Q1, and we have a very strong pipeline for NovaSeq instrument placements, particularly in clinical end markets; we are also raising our profitability expectations for the year because of the Q1 overperformance. So we now anticipate operating margins of 23.4% to 23.6%, which is 10 basis points higher than our previous guidance at the midpoint.

Ankur Dhingra

executive
#4

That works out to roughly 140 basis points of margin growth compared with 2025 on a year-over-year basis, once you set aside what acquisitions contributed. In the same way, we're lifting both the low end and the high end of our 2026 EPS guidance by $0.10, and our expectation now is non-GAAP diluted EPS between $5.15 and $5.30. If you leave out what the SomaLogic acquisition brings, that works out to EPS growth of 12% at the midpoint. Turning to our Q2 '26 guidance; for Rest of World we anticipate organic revenue growth between 4% and 6%, along with reported revenue between $1.12 billion and $1.14 billion, and non-GAAP EPS between $1.20 and $1.25. Because demand and pipeline for NovaSeq X remain strong, we're putting investment into scaling up supply of NovaSeq X units, and we expect the team to keep making headway across Q2 and on into Q3 too. Our guidance assumes operating margins around 22%, which reflects a richer mix of instruments revenue along with the associated investments, near-term inflationary pressure tied to freight costs, a higher cost of electronic components, and a full quarter of SomaLogic as well. On those inflationary pressures, we're pursuing a number of mitigating steps so the impact is fully offset across the year, and that shows up in the implied margin improvement for the remainder of the year. Our strong Q1 performance, together with a clinical installed base that's growing quickly, gives us a good setup as we head into the back half of the year. And once these Xs come online, they'll contribute to the consumables revenue stream; this better outlook also gives us confidence in the headway we're making toward hitting our long-range targets for revenue, margin and EPS growth by 2027. Setting aside what acquisitions contributed, our guidance implies roughly 350 basis points of margin expansion by the end of 2026, which represents meaningful headway toward the 500 basis point target by 2027. That captures the underlying improvement in our operating model even as we navigate a dynamic and inflationary macro environment; to wrap up, I want to thank the Illumina team for their continued focus and disciplined execution throughout the quarter. We're off to a great start in 2026, and I'm extremely encouraged by the headway we've made in returning Illumina to long-term sustainable revenue and earnings growth. Thank you for joining our call today. I will now invite the operator to open the line for Q&A.

Vijay Kumar

analyst
#5

Nice quarter — congratulations on the clean print. I'll keep it high level and stick with guidance for my one question. Put simply, you topped Q1, landing above the upper end of your organic assumptions. Instruments performed better, clinical performed better. You've lifted the instrument guidance for the year. What I'm wondering is why the organic number for the year wasn't taken up. Is there some prudence you're building in? What would that prudence consist of? Why can't clinical keep up 20%? I'm just asking about the assumptions behind the guide.

Jacob Thaysen

executive
#6

Vijay, Jacob here, and thank you so much. We agree — we're off to a terrific start in 2026 with a strong Q1 performance. Like you said, we keep seeing really strong momentum in the clinical business. In fact, we believe that will carry on, not just through the remainder of the year, but into the years ahead as well. So we're very excited about that ongoing momentum. As also noted, we had a strong Q4 for instrument placements, and we carried that strength into Q1 and have a solid pipeline for the quarters ahead. So we feel really good about where we stand. We know that when we place instruments, they'll begin bringing in revenue — or consumables revenue — roughly 6 months after installation. So there's certainly plenty of optimism about how we can see the second half of the year too; so on the whole, we're pleased about that. Now we're only 1 quarter into the year; so I think really, it's that we're leaning in by lifting both the top line and the bottom line early — very early in the quarter. So I think we're signaling all the right things here. Ankur?

Ankur Dhingra

executive
#7

Appreciate that, Jacob. Vijay, the thing I'd put on top of what's been said is that our revenue guidance is being lifted. That figure is climbing by $20 million, equivalent to approximately 0.5 point. What I said about us now plainly aiming at the upper portion of the range instead of the midpoint is a reflection of that, and it remains inside the range we previously discussed. So decimal points shift, and because of that, the percentage comes out as it does. That's all there is to it.

Puneet Souda

analyst
#8

Congratulations on the progress you've made with instrumentation — it's really been remarkable. I'm simply attempting to understand it better: of that overall blend, what portion is driven by clinical work as opposed to research? When it comes to these customers, what kind of momentum are you seeing in research? And once these instruments start being adopted, a shift is going to take place. Those labs will initially feel an effect as consumable pricing moves from 6,000 to Nova X. How are you accounting for that influence? And is it already reflected in the guidance? Perhaps you could elaborate on the instrumentation strength you're witnessing and explain how we should think about instrumentation for 2Q and for the entire year.

Jacob Thaysen

executive
#9

Sure. Thank you, Puneet. That seemed like a single question containing several parts, so I'll do my best to touch on a handful of those. Broadly speaking, just as you pointed out, the placements we completed during Q1—and during Q4 as well—leave us quite happy. That momentum is still showing up, and it tells us our customers recognize that once they purchase an X, we'll keep pushing innovation forward. They understand, then, that Illumina will stand alongside them, making sure they can keep generating fresh insights from those instruments, whether in the clinical space or in the research space. So we're going to keep at it. At AGBT, I believe we made a strong impression demonstrating the innovations we're pursuing on the X platform. Customers are evidently buying X platforms in order to generate additional business on them. We're now witnessing many of these placements. Growth is happening in both research and clinical placements; however, looking at clinical—which accounts for over 60% of placements—these represent far more incremental additions rather than replacements drawn from the 6,000. So I think you'll soon observe that this also fuels immediate top-line growth. Looking at it from the research side, what we keep observing is that big projects are still being executed on that platform, and plenty of single-cell work continues to run there too, yet the overall blend of where research activity is headed hasn't shifted in any meaningful way so far. That said, we're genuinely enthusiastic about several new innovations we'll be rolling out in the coming stretch. Spatial stands out as one that should generate extra upside late this year and on into '27. And as we also reminded ourselves, we've now converted the majority of our Xs within the research business. As soon as this market recovers, we won't face the same pricing pressure that we did previously, and because of that, we'll be able to see — growth can come to us through that route.

Ankur Dhingra

executive
#10

Thanks, Jacob. From the standpoint of the pricing transition, the one point I'd tack on is that our assumptions remain the same. As we've discussed, we anticipate the clinical transition will carry on. And every one of those pricing assumptions is already reflected in the guidance.

Tycho Peterson

analyst
#11

Ankur, staying on the topic of instruments, could you put a number on the backlog? You mentioned that supply has been a constraint. I realize the 10-Q will cover this, but can you tell us the amount you were unable to ship? Then, thinking about the road map, Jacob, there's this question of whether the market freezes. Could you address how we can feel confident that during the next 18 months, no problem arises with the road map you've set out?

Jacob Thaysen

executive
#12

Let me begin by noting that the instrument placements we've made indicate no market we compete in is freezing at this moment. That gives us a lot of confidence. Our instrument funnel for the coming period also looks encouraging to us. Regarding our road map shared at AGBT, we're advancing on the X with the launch of new flow cells, and beyond that, as I noted, spatial TruPath plus our 5-Base is gaining momentum. We're optimistic about the clinical side as well as what we can bring to research once that area recovers; therefore, from where we stand today, we anticipate no meaningful shift in the competitive landscape. We recognize there is considerable chatter out there. We're eager to compete once they at last enter the market.

Ankur Dhingra

executive
#13

Absolutely. And Tycho, regarding what's happening with the instruments themselves, demand has been extremely strong. Our pipeline is really solid. In the 10-Q, you'll notice that performance obligations rose over 20% compared to a year ago. A large share of that comes from instruments as well as consumables. My expectation is that placements in Q2 may land near where we were in Q1, and the pipeline across the rest of the year also appears strong. Like we said, we're ramping up. Demand appears quite strong. And I'd add, as Jacob noted, a considerable portion of this demand stems from new trials and new tests.

Doug Schenkel

analyst
#14

This is Madeleine, filling in for Doug. I just have one quick question regarding the operating margin. My understanding is that Q2's operating margin landed slightly below what the Street expected. You mentioned certain headwinds, among them investment to scale the supply, and those ought to persist through Q3. What's the right way for us to frame how the margin moves across the year? And how does the ramp from that Q2 margin toward the year-end exit rate look?

Jacob Thaysen

executive
#15

Yes. Madeleine, thank you. Let me begin there. This is Jacob. If we just step back for a moment and consider what Illumina has managed to accomplish across the past few years, our margins have improved tremendously. As you likely remember, during '24, we set out our strategy of building back to high single-digit growth in '27. I think it's clear now that we're moving into that, with flattish growth last year, and now we're beginning to see mid-single-ish growth, and we will now move into high single-digit growth for next year. So on the top line, we're on a great trajectory toward reaching that. On the operating margin, we're likewise demonstrating great progress on those elements. So each quarter has some puts and takes. As we said, as Ankur was saying, inflationary pressure exists in the rest of the year here, and we're going to offset it. So that is what you actually see reflected in our short term and also the longer-term guidance. Ankur, do you want to chime in here?

Ankur Dhingra

executive
#16

Absolutely. Regarding Q2 in particular, there are a handful of factors at play. Compared with the same period a year earlier, our instrument mix is significantly richer; we're also facing cost pressures tied to items such as components and freight, among other things, plus SomaLogic will be consolidated into our results for the entire quarter. That said, we've begun putting a set of offsetting measures into motion here in Q2, though we expect their impact to show up starting in Q3 and continuing through Q4. As a result, we're encouraged about the step-up in operating margin during the back half relative to the front half.

Dan Brennan

analyst
#17

Great. I recall that previously you provided some detail on the slide deck about X customers who had already converted and those who were partway through converting; and Jacob, I know you touched on that somewhat, considering where we are today with the conversion. Could you perhaps elaborate a bit on this year's guidance, especially regarding the clinical side and how we should think about the context of those two? And might there be some acceleration as that conversion occurs later in the cycle?

Jacob Thaysen

executive
#18

Yes, Dan, I believe there's still a mix of various customer types. As we — I think we've also said this before — there are customers who have chosen to remain on the 6K platform for a longer duration. Those are likely the — these are clinical customers who have a regulated assay on those and an FDA-approved assay who either believe they are well served by the 6K platform or that transitioning it over requires much more time. So that represents some of what I'd call the laggards in the transition. For many others, they are in the process of — they've already transitioned. There will always be a certain number of customers, a certain number of assays that will remain on the former platform at least for some time. And so, we're also saying that, as Ankur mentioned in the prepared remarks, by the end of this year, we feel we have fundamentally transitioned the business that will transition, and then there will be a long tail of transition ahead. Overall, we view the clinical business as an opportunity for growth. We don't see any deacceleration in that business at the moment.

Patrick Donnelly

analyst
#19

Perhaps a question about the research and applied markets. My understanding is that you're still referring to a decline in the mid- to high single digits for the year. Consumables appear to have fallen 12% during the quarter, compared with a fairly easy comp. Could you describe what you're hearing from customers in that area? Is there a hope that this market will get somewhat better as the year progresses and budgets are finalized? What's your sentiment on that market? And then one quick housekeeping item for Ankur. In which line does SomaLogic revenue appear — instruments or consumables? I just want to be sure I'm following it correctly.

Jacob Thaysen

executive
#20

Thanks, Patrick; let me begin with the research space. What makes us genuinely glad is that there appears to be alignment from DC regarding the commitment to NIH funding. And we do think that although funding has been slow early in the year, it will accelerate in — over the course of the year. So that's an excellent headline. Now I think there are far more specifics behind that, which we also discussed last quarter and why we are more conservative on the research business here in 2026; and that is that one matter is having released grants, but the other matter is having all of that converted into spending money on actual tools and consumables. And there is definitely some cautiousness among our customers before they truly understand how those grants — who is receiving the grants and how many grants are being received, there will be some cautiousness in that space for a little while; but we do think that we ought to see a somewhat improved environment over the course of the year. That said, we haven't incorporated much of that into our guide at this point. So I view that more as an upside.

Ankur Dhingra

executive
#21

Patrick, something else I'd mention regarding that market: keep in mind, over 90% of the volume for that end market has been transitioned by us, and our pricing comparison ought to continue improving for that market across the year too. So that covers that. Regarding SomaLogic, from the standpoint of our reporting, it falls under microarrays — largely within microarrays.

Subbu Nambi

analyst
#22

Apologies — I'm following up on something that came up earlier. You've now recorded 20% growth in clinical across 2 straight quarters, so is it reasonable to expect that momentum to carry on through the year? Is there any basis for thinking the guidance could shift well past its upper boundary? In your low-end scenario, academia declines at a mid-single-digit rate while clinical sits in the low double digits; at the high end, academia falls by a low single digit and clinical lands in the teens.

Jacob Thaysen

executive
#23

Right, Subbu — as you pointed out, we're quite happy with the momentum in clinical, obviously across the last 2 quarters, and in fact all the way through '25 as well. And because we keep moving a growing share of revenue into the consumables business on the X platform, that pricing pressure is moving into the rearview, and we expect that to remain a source of strong growth. So yes, right now we still view mid-teens growth as a solid result for the clinical market. If it came in above that, it would represent potential upside relative to what we've forecast.

Ankur Dhingra

executive
#24

Looking at how things stand with the business and Subbu, right now we aren't — we don't see any indication that this market might slow down as such. Momentum is solid in that area.

Kyle Mikson

analyst
#25

Solid quarter. To build on what looks like a fairly small bump to the '26 revenue outlook: was that range revised because of rivals entering the market this summer? Since we now know their pricing — $150 per genome, plus appealing pricing for accounting applications — do you anticipate a bigger headwind, and maybe you built in some buffer with this updated range?

Jacob Thaysen

executive
#26

Honestly, I feel pretty good about the raise we just made. One quarter in, we're already lifting our guidance. That's worth taking some pride in, and it demonstrates once more our dedication to this year and our confidence in where things are headed. Like we mentioned last quarter, our competitive standing is something we're very sure about. From what we observe in the first half on the competitive front, I doubt that pattern shifts much in the second half. So our position feels solid; we've factored in our expectations for how the business will unfold, and that's exactly what our guide shows.

Dan Arias

analyst
#27

Jacob, maybe a brief follow-up regarding your earlier points. Obviously, that upcoming 35B flow cell is significant in this rivalry we're discussing. I'd assume customers are inquiring about what a like-for-like expense evaluation would be relative to that $150 price point. When you're presenting run economics to those assessing them and attempting to predict future outcomes, what cost per G, or cost per genome, do you intend to provide?

Jacob Thaysen

executive
#28

Correct. Dan, in my view, considerable room remains within the market segment we serve. When you think about clinical applications, and you think about the rare disease sector transitioning from exome to genome, that shift will require sequencing intensity that's 15 times greater. Whenever we speak with clients who do a great deal of exome work and who are looking for our assistance in moving them toward genome, we find it quite easy to have a productive discussion regarding elasticity and regarding ways we can generate profitable growth for ourselves while, naturally, continuing to bring down their cost per gigabase; this creates a solid win-win outcome for both parties. That's only a single illustration. But it's a dialogue we maintain with our customers to confirm that opportunities exist in this area. When it comes to that topic, what drives it for us is a volume-versus-price trade-off: offering steep discounts tends to trigger equally steep unit growth. So we keep revisiting that discussion, and it comes up often. As for the 35B, we aren't prepared right now to publicly discuss its price point. We'll address that once we get nearer to the X launch.

Catherine Ramsey

analyst
#29

The figures for X placements are genuinely heartening. Well done on kicking off the year so strongly. However, might you take a moment to discuss how things look regarding placements within the low and mid-throughput portions of our portfolio?

Jacob Thaysen

executive
#30

Sure, Catherine. Taking low throughput first — and just to remind everyone, our MiSeq i100 came to market slightly over 12 months back, at the close of '24, I believe, or at the start of '25. Placements during '25 proved extremely robust; we have publicly reported upwards of 1,000 units placed. That forward drive is carrying over into '26 as well, so there's plenty of positive movement and momentum behind both the MiSeq i100 business and its placements. As for mid-throughput, this area has posed somewhat greater difficulty over a longer horizon because of the macro backdrop — where, naturally, the MiSeq 100 is capturing a portion of the lower end of that business, and we additionally observe customers moving upward into the high throughput segment. Yet within that middle tier, the customers there tend to be the ones most attuned to macro conditions, which may be pausing certain investments while they await a different kind of environment. A number of them aren't engaged in production-mode sequencing, so they're seeking greater flexibility. Thus, even though performance in that market looks solid, we hold the view that once conditions shift — particularly within the research segment — that market will expand at an even better rate for us.

Casey Woodring

analyst
#31

Yeah, just a couple of quick things to follow up on what was asked before. Did you put a number on the drag coming from inflation on items such as memory chips and freight that you intend to make up for during this year? Then regarding NovaSeq X placements, you had 80 during the quarter. From what I heard, it seems you're expecting a comparable figure in 2Q, if I caught that correctly. And then what's the right way to think about X placements across the back half?

Jacob Thaysen

executive
#32

Yeah. Let me begin at the broadest level regarding how we've handled a few of the surprises, I'd call them, that have come Illumina's way in particular, though the market as a whole too, broadly speaking, across the past several years. If you've tracked our results and the way we've tackled various kinds of cost difficulties, the Illumina team has performed admirably in discovering methods to make up for that. We keep pushing an extremely, extremely strong emphasis on operational discipline; and that's the engine driving things here. You're able to observe that when this headwind shows up ahead of us, we are — we discover methods to work through it. And I believe the team feels quite energized by that. A great deal of energy is being poured into this, saying we can — that our commitments can be delivered on; so the team's performance has me very pleased. Ankur, would you like to say a bit about the...

Ankur Dhingra

executive
#33

Absolutely. Thanks, Jacob. And indeed, that falls inside the bounds we can act on and pursue plenty of steps to lessen this too. Regarding the Xs, correct, you're right. I brought up being comparable to Q1 amounts in Q2 as well. And based on how things appear at present, the pipeline for the back half likewise appears pretty strong. That means overall, across the entire year, we anticipate landing somewhat higher than the guidance we gave when the year began.

Jack Meehan

analyst
#34

I'd like to continue probing Nova X demand; from what I can tell, it's been strong. Could you give us additional detail about which clinical customers are showing the heaviest interest? I'm wondering whether you might expand on areas such as multi-cancer, MRD, therapy selection, women's health. Does anything particularly stand out?

Jacob Thaysen

executive
#35

Sure, Jack, I appreciate the question; the answer is basically all of the above, which is to say we're seeing wide-ranging interest in the X. Naturally, we also have big customers, centralized labs based in the U.S. that see — as you can tell from their own figures, they see considerable momentum on the oncology side. And we're witnessing substantial dedication to keep expanding there. That said, I'd describe it as spanning oncology, rare disease, and of course NIPT as well, plus across the regions; so truly strong results in the clinical area. And I believe that really reflects the strength and the chance that exists in that space moving forward.

Michael Ryskin

analyst
#36

I want to revisit Nova X, since that placement figure stands out as the largest shock versus what our model anticipated. Is there anything you can share about pricing, or simply how you're moving those units out the door, and where that additional demand originates? Looking at the past 2 years, you'd held fairly consistent — apart from 4Q, when you get a pleasant bolus — at 50 to 60 each quarter across those 2 years; now you're leaping to 80 in 1Q and 80 in 2Q, yet your instrument revenue figure for 1Q came in at $118 million. Given 80 placements, we'd have figured something nearer to $125 million, $130 million — so is discounting of some kind happening here? What exactly is behind that substantial jump in demand?

Jacob Thaysen

executive
#37

Yes. Allow me to begin addressing that. To start with, consider the X placements. When an X gets placed, the reason is that you've got a chance to — whenever a customer places or purchases an X from us, the point isn't for it to gather dust in a corner; the point is to generate consumables revenue from it. As we've also said, at JPMorgan we presented data showing we're at roughly above $1.3 million of pull-through on the Xs. We expect that to stay at that level, or perhaps higher; so our aim is to get as many Xs into the field as possible so they can fuel that consumables growth across the coming many, many years. That matters most to us. Second, naturally, when we have customers — and we do, as we've discussed previously — placing orders of 5 or 10 or even more than that, we obviously extend a volume discount on those X placements; we consider that fair. Still, our primary objective remains getting Xs into the field and driving consumables. We aren't placing them merely so they can sit in a corner.

Ankur Dhingra

executive
#38

The one point I'd tack on to that, Mike, is that certain instruments inside 83 likewise follow a reagent-style or leasing-type arrangement, and you'll consistently find a few of those instruments in the mix, which naturally carry a distinct way of recognizing revenue.

Mason Carrico

analyst
#39

Plenty has already been covered, but given the recent competitive announcements, perhaps you could discuss where you see Illumina winning in spatial? Is it more a case of a rising tide lifting every boat? Or are there distinct pockets of the market where Illumina can differentiate itself?

Jacob Thaysen

executive
#40

Yeah, the spatial opportunity has us excited, and we showed off our spatial offering both at ASG and at AGBT, drawing considerable interest from customers. So we genuinely believe our spatial solution carries a lot of value. Broadly speaking, I agree with what you said — right now it's lifting every boat. I also appreciated seeing what 10x launched. Honestly, I'm quite impressed by what Serge and his team have delivered. I'm a big admirer of that work. And I truly believe it generates far more overall interest in spatial; that being said, these are distinct technologies. They're serving a somewhat different customer segment. So there's ample room for quite a few players in that space. And Illumina intends to compete; we're here to — much of our spatial technique has been developed alongside our customers. So we understand well what they want; we understand well where our opportunity lies; and I'm quite confident we'll have a winner when we bring our spatial solution to market later in the year.

Kyle Mikson

analyst
#41

Regarding that slide in the deck about the NovaSeq X transition, there's one element showing the share of consumables revenue, and versus the fourth quarter it's held steady at 55%. But the GB shipped volume that NovaSeq X accounts for has been climbing quite well, heading toward roughly 80%, 90%; so what actually occurred, I suppose, during the first quarter that caused it to ease off somewhat? And will it shift direction from here? Should we be looking for 55%, perhaps something in the high 50s, to hold going forward?

Jacob Thaysen

executive
#42

Nothing — my view is that on a quarter-by-quarter basis, and I believe we brought this up in prior quarters as well, examining this figure with too much precision carries some risk. It reflects a trend direction, and from one quarter to the next it can move somewhat up or down; so I wouldn't read too much into it. What you ought to observe is that we keep transitioning our clinical customers quite well; and as Ankur said, we think we'll have surpassed 85% of that transition by the close of this year, which in our view is the point where the transition — where we then sense that we are — the transition sits behind us.

Conor McNamara

executive
#43

We appreciate everyone being with us on this call. A recording of today's session can be found in the Investors area of our site. That wraps up our discussion, and we hope to connect with you at events coming up.

Operator

operator
#44

That wraps up the call for today. Thanks for joining us. At this point you're free to hang up, and we hope the rest of your day goes well.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Illumina, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Illumina, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Illumina, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.